ストックスクリーナーアプリを入手
107.13
4.99%
5.09
前日終値:
$102.04
開ける：
$104.48
24時間の取引高:
1.58M
Relative Volume:
1.62
時価総額：
$6.53B
収益：
$521.31M
当期純損益:
$-23.36M
株価収益率:
-224.07
EPS:
-0.4781
ネットキャッシュフロー:
$54.87M
1週間 パフォーマンス:
+7.63%
1か月 パフォーマンス:
+12.19%
6か月 パフォーマンス:
+52.43%
1年 パフォーマンス:
+110.89%
1日の値動き範囲:
$104.34
$107.71
1週間の範囲:
$99.02
$107.71
52週間の値動き範囲:
$47.89
$114.99
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
107.13 | 6.53B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-09-24 | 開始されました | TD Cowen | Buy |
| 2025-08-11 | 再開されました | Stifel | Buy |
| 2025-05-19 | 再開されました | H.C. Wainwright | Buy |
| 2024-04-17 | 開始されました | Stifel | Buy |
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum Shareholders Approve Directors, Auditors and Compensation - The Globe and Mail
Mirum Pharmaceuticals StockAnalyst views and sector check at week’s end - AD HOC NEWS
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum (MIRM) SVP Jolanda Howe sells 2,594 shares under Rule 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals, Inc. (MIRM) reports Q1 loss, beats revenue estimates - MSN
Mirum Pharmaceuticals (MIRM) stockholders back 2026 directors, auditor and pay package - Stock Titan
MIRM, INCY report positive rare disease data as FDA begins NDA review - MSN
Mirum Pharmaceuticals Inc (MIRM) Institutional Confidence - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mirum Pharmaceuticals (MIRM) director receives deferred stock units and options grant - Stock Titan
Mirum Pharmaceuticals (MIRM) director granted new options and deferred stock units - Stock Titan
Director at Mirum (MIRM) awarded deferred stock units and options - Stock Titan
MIRM (NASDAQ) director plans sale of 2,594 shares via Morgan Stanley - Stock Titan
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
Avoiding Lag: Real-Time Signals in (MIRM) Movement - Stock Traders Daily
Mirum Pharmaceuticals Inc (MIRM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRM Maintained by Citizens -- Price Target Raised to $146 - GuruFocus
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target on drug deal By Investing.com - Investing.com Australia
Citizens raises Mirum Pharmaceuticals stock price target on drug deal - Investing.com
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - lincolnjournal.com
Here's what key metrics tell us about Mirum Pharmaceuticals (MIRM) Q1 earnings - MSN
MIRM Maintains Overweight Rating -- Price Target Raised to $150 - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan Stanley - MarketBeat
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares - Investing.com UK
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares after option exercise - Stock Titan
CenterBook Partners LP Purchases 37,010 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Clearbridge Investments LLC - MarketBeat
Mirum (MIRM) President and COO exercises options, boosts direct share holdings - Stock Titan
5,000-share resale notice for MIRM (NASDAQ: MIRM) affiliate; prior sale noted - Stock Titan
Mirum Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates Significantly, Shares Edge HigherEarnings Quality Analysis - newsline.com
Mirum Pharmaceuticals (MIRM) Edges Higher as Bulls Test Resistance Near $98BPI Bear Confirmed - newsline.com
Mirum Pharmaceuticals, Inc. Balance Sheet – XETR:08D - TradingView
EBITDA of Mirum Pharmaceuticals, Inc. – XETR:08D - TradingView
Discipline and Rules-Based Execution in MIRM Response - Stock Traders Daily
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report? - Yahoo Finance
Earnings call transcript: Mirum Pharmaceuticals Q1 2026 results reveal strong revenue growth - Investing.com
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - BioSpace
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com Canada
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):